[1]Patent:WO2009/81195,2009,A1.Locationinpatent:Page/Pagecolumn57
[1]Patent:WO2009/81195,2009,A1.Locationinpatent:Page/Pagecolumn58-59
[1]Patent:WO2009/81195,2009,A1.Locationinpatent:Page/Pagecolumn168-169
[1]Patent:WO2009/81195,2009,A1.Locationinpatent:Page/Pagecolumn51
[1]Patent:WO2009/81195,2009,A1
Title: Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687).
Journal: Journal of medicinal chemistry 20121213
Title: Barlind JG, et al. Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). J Med Chem. 2012 Dec 13;55(23):10610-29.
Title: Denison H, et al. Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial. Diabetes Obes Metab. 2013 Oct 4.
Title: Eike Floettmann, et al. Pharmacological inhibition of DGAT1 induces sebaceous gland atrophy in mouse and dog skin while overt alopecia is restricted to the mouse. Toxicol Pathol. 2015 Apr;43(3):376-83.
